Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 273

The DOI matches its Crossref record; 285 of the 285 references it cites were found in a registry or an index.

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

Open access
Scherpereel, Arnaud, Opitz, Isabelle, Berghmans, Thierry, Psallidas, Ioannis, Glatzer, Markus, Rigau, David, Astoul, Philippe, Bölükbas, Servet, Boyd, Jeanette, Coolen, Johan, De Bondt, Charlotte, De Ruysscher, Dirk, Durieux, Valerie, Faivre-Finn, Corinne, Fennell, Dean, Galateau-Salle, Francoise, Greillier, Laurent, Hoda, Mir Ali, Klepetko, Walter, Lacourt, Aude, McElnay, Phil, Maskell, Nick A., Mutti, Luciano, Pairon, Jean-Claude, Van Schil, Paul, van Meerbeeck, Jan P., Waller, David, Weder, Walter, Cardillo, Giuseppe, Putora, Paul Martin·2020·European Respiratory Journal

Abstract

The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009–2018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in ∼10% of cases, justifying the use of specific markers, including BAP-1 and CDKN2A(p16) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pre-therapeutic assessment. Monitoring: patient's performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.00953-2019

Cites

285 of 285 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 285 references

Cited by

See all 273

Metadata

Authors
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., De Bondt, C., De Ruysscher, D., Durieux, V., Faivre-Finn, C., Fennell, D., Galateau-Salle, F., Greillier, L., Hoda, M. A., Klepetko, W., Lacourt, A., McElnay, P., Maskell, N. A., Mutti, L., Pairon, J.-C., Van Schil, P., van Meerbeeck, J. P., Waller, D., Weder, W., Cardillo, G., & Putora, P. M.
Venue
European Respiratory Journal
Published
2020-05-25
Volume
55
Issue
6
Pages
1900953
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W3028094831
Cited by
273
References
285
FWCI
20.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. https://app.cochat.ai/papers/10.1183/13993003.00953-2019
The paper
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., De Bondt, C., De Ruysscher, D., Durieux, V., Faivre-Finn, C., Fennell, D., Galateau-Salle, F., Greillier, L., Hoda, M. A., Klepetko, W., . . . Putora, P. M. (2020). ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Respiratory Journal. https://doi.org/10.1183/13993003.00953-2019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.